Phase 2 Stomach Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with a specific type of rare brain tumor called an embryonal tumor with multilayered rosettes (ETMR), confirmed through laboratory testing of tumor tissue.
• Sufficient tumor tissue samples must be available (a specific number of tissue slides or a tissue block with enough tumor content), as required by the study team.
• People of any age may be considered for this trial.
• Participants in Group 1 must not have received any cancer treatment before joining, other than surgery to remove the tumor.
• Participants in Groups 2 and 3 may have received prior cancer treatment before joining, but the study chairs must review and approve their case first.
• No prior radiation therapy for this tumor must have been received.
• Treatment should begin within 28 days of the most recent surgery; cases starting later must be discussed with the study chairs.
• Each group has specific eligibility requirements: Group 1 requires complete tumor removal, no spread of disease, and eligibility for early radiation therapy; Group 2 requires complete tumor removal, no spread of disease, and eligibility for high-dose chemotherapy; Groups 3A and 3B are for people with disease that has spread or could not be fully removed, treated with radiation or high-dose chemotherapy respectively.
• For groups receiving radiation, age requirements apply: the child must be older than 12 months for tumors in the lower part of the brain, or older than 15 months for tumors in the upper part of the brain, at the time radiation is planned. The parent or guardian and the treating doctor must also be willing to use radiation as part of treatment.
• A person's general health and ability to function must meet a minimum score on a standard medical scale (confirm with trial site for exact score requirements). People who use a wheelchair due to paralysis may still meet this requirement.
• Blood counts must be at an acceptable level: white blood cell counts and platelet counts must both be above certain minimums, and platelets must not have been received via transfusion in the 72 hours before joining.
• Kidney function must be within an acceptable range based on age and sex.
• Liver function tests must be within acceptable limits.
• People with a seizure condition may still be considered if their seizures are well controlled, though certain seizure medications may affect eligibility (confirm with trial site).
• People of childbearing potential must agree to use reliable contraception during the study and for 4 months after treatment ends. If pregnancy occurs or is suspected during participation, the treating doctor must be told immediately.
• Enrollment in a related study called PNOC COMP is required before joining this trial, if that study is open at the treating institution.
• A parent, legal guardian, or the patient themselves must be able to understand and sign the required consent forms.

Who may not be able to join:

• People in Group 1 who have already received any cancer-directed treatment other than surgery.
• People who are currently receiving another experimental cancer treatment as part of a different study.
• People with a history of serious allergic reactions to medications that are similar to those used in this trial.
• People with a serious illness or medical condition that is not currently under control.
• People who are pregnant or breastfeeding.

Important: Always verify eligibility with the trial site directly before applying.